Katz Matthew H G, Choi Eugene A, Pollock Raphael E
The University of Texas, MD Anderson Cancer Center, Department of Surgical Oncology, Houston, TX 77030, USA.
Expert Rev Anticancer Ther. 2007 Feb;7(2):159-68. doi: 10.1586/14737140.7.2.159.
Radical surgical resection currently represents the most effective therapy for patients with retroperitoneal sarcoma. Unfortunately, margin-negative resection often mandates extirpation of multiple retroperitoneal viscera, and such operations are nonetheless fraught with high rates of locoregional recurrence. In an attempt to improve local control and ultimately survival, adjuvant strategies of radiation and chemotherapy have been increasingly employed, with promising results. To date, however, the rarity of the disease has limited large, prospective studies investigating the efficacy of these adjuvant modalities. In this article, we review the current literature pertaining to the diagnosis, staging and treatment of retroperitoneal sarcoma and demonstrate the critical need for future large, multi-institutional studies to advance our knowledge of this uncommon disease.
根治性手术切除目前是治疗腹膜后肉瘤患者最有效的方法。不幸的是,切缘阴性的切除往往需要切除多个腹膜后脏器,而这类手术仍存在较高的局部区域复发率。为了提高局部控制率并最终提高生存率,放疗和化疗的辅助策略已越来越多地被采用,且取得了令人鼓舞的结果。然而,迄今为止,该疾病的罕见性限制了对这些辅助治疗方式疗效进行大规模前瞻性研究。在本文中,我们回顾了目前关于腹膜后肉瘤诊断、分期和治疗的文献,并表明迫切需要未来进行大规模、多机构研究,以增进我们对这种罕见疾病的了解。